---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274071"
form_type: "8-K"
ticker: "HCA"
cik: "0000860730"
company_name: "HCA Healthcare, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:17:25.301598+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HCA targets 4-6% EBITDA, 8-12% EPS growth over 5 yrs; 2024 within ranges

## Summary
- Adjusted EBITDA growth target of 4% to 6% annually over next five years.
- Diluted EPS growth target of 8% to 12% annually over next five years.
- 2024 expectations fall within those ranges, after resolving Q1 commercial payer dispute.
- More detailed 2024 guidance to be provided in January year-end call.

## SEC filing metadata
- accession: 0001193125-23-274071
- form_type: 8-K
- ticker: HCA
- cik: 0000860730
- company_name: HCA Healthcare, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/860730/000119312523274071/0001193125-23-274071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/860730/000119312523274071/d263099d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274071
- JSON: https://secwatch.observer/filing/0001193125-23-274071.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.